Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CA11 | O75493 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GLS | O94925 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629408 | 0.86 | CA1 (0.62) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL2442194 | 0.80 | TP53 (0.47) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL4717366 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2ATDP1CSNK2A1 | |
| SCHEMBL2629359 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL10995810 | 0.77 | CA1 (0.58) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL8246439 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL10878301 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL8356753 | 0.75 | TP53 (0.46) | SMN1; SMN2CA1CA2MEN1KMT2A | |
| SCHEMBL20522351 | 0.75 | CSNK2A2 (0.70) | SMN1; SMN2CA1CA2CA4CA5A | |
| SCHEMBL11884256 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-5126339-A | Antihistamine, antiserotonine | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-06-30 | — | — | US | disclosed |
| US-5025014-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-18 | — | — | US | disclosed |
| EP-0151824-B1 | N-(4-PIPERIDINYL) BICYCLIC CONDENSED 2-IMIDAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-04-04 | — | — | EP | disclosed |
| US-4888426-A | CHEMICAL INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-12-19 | — | — | US | disclosed |
| US-4695569-A | ANTIALLERGENS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-09-22 | — | — | US | disclosed |
| US-4588722-A | ANTIHISTAMINES, ANTIALLERGENS | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-05-13 | — | — | US | disclosed |
| EP-0151824-A2 | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-08-21 | — | — | EP | disclosed |
| EP-0144101-A2 | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | PTGIR, PTGIS, CA2 | SMN1; SMN2 3728/4885CA1 149/4885CA2 3/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | SMN1; SMN2 3728/4885CA1 149/4885CA2 3/4885 |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | SMN1; SMN2 3728/4885CA1 149/4885CA2 3/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | SMN1; SMN2 315/4885CA1 1738/4885CA2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.